What is AtriCure, Inc.'s earnings per share (EPS)?

AtriCure, Inc. (ATRC) reported diluted earnings per share of -$0.24 for fiscal year 2025. This represents a 74.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AtriCure, Inc. (ATRC) Financials

ATRC

Trailing 12 months to June 30, 2026

Revenue $569.6M +13.9% YoY

Net Income $10.6M +129.0% YoY

EPS (Diluted) $0.21 +127.3% YoY

Free Cash Flow $53.1M +110.0% YoY

Market Cap $2.9B as of Oct 14, 2026

Price / Sales 5.1x on $569.6M revenue, trailing 12 months to June 30, 2026

Price / Earnings 274x on $10.6M net income, trailing 12 months to June 30, 2026

Price / Book 5.6x on $516.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 27, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATRC SEC filings page.

AtriCure, Inc. (ATRC) reported $569.6M in revenue over the twelve months to Jun 30, 2026, up 13.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATRC FY2025 2026-10-03

Revenue growth is finally reaching the bottom line, while cash generation improves faster than reported earnings.

From FY2023 to FY2025, gross margin stayed near 75.0% while operating margin improved from -6.7% to -1.8%; the shift points to better expense absorption rather than a richer gross-profit mix. FY2025 operating cash flow of $57.3M and free cash flow of $48.3M arrived while the company still reported a net loss, so cash conversion is currently ahead of accounting profitability.

Revenue rose 14.9% in FY2025 while gross margin held at 75.0%, showing expansion without a change in underlying unit economics. The near-breakeven operating result indicates that higher sales are absorbing overhead more effectively, although profitability has not yet fully crossed over.

The balance sheet remains lightly debt-funded, with debt-to-equity at 0.1x and the current ratio at 4.0x, but working capital is growing with the business. Inventory and receivables reached $78.5M and $66.7M, respectively, tying more resources to future sales even as cash flow improves.

Financial Health Signals

Financial Health Score 57/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of AtriCure, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

AtriCure, Inc. has an operating margin of -1.8%, meaning the company loses $2 on every $100 of revenue. This results in a profitability score of 19/100. This is up from -8.6% the prior year.

Growth

AtriCure, Inc.'s revenue grew 14.9% year-over-year to $534.5M, a solid pace of expansion. This earns a growth score of 77/100.

Leverage

AtriCure, Inc. carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.96, AtriCure, Inc. holds $3.96 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.

Cash Flow

AtriCure, Inc. has a free cash flow margin of 9.0%, earning a moderate score of 41/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

AtriCure, Inc. posts a -2.3% return on equity (ROE), meaning it loses $2 for every $100 of shareholders' equity. This results in a returns score of 21/100. This is up from -9.7% the prior year.

Altman Z-Score Safe

11.03

AtriCure, Inc. scores 11.03, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.9B) relative to total liabilities ($162.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

AtriCure, Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

AtriCure, Inc. reported a net loss of $11.4M while generating $57.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

AtriCure, Inc. reported an operating loss of $9.4M against $5.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$153.6M

YoY+12.8%

QoQ+8.7%

5Y CAGR+16.6%

10Y CAGR+14.5%

AtriCure, Inc. generated $153.6M in revenue in Q2 2026. This represents an increase of 12.8% from the same quarter a year earlier. Against the prior quarter it is up 8.7%.

EBITDA

$15.2M

YoY+2107.0%

QoQ+151.3%

AtriCure, Inc.'s EBITDA was $15.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2107.0% from the same quarter a year earlier. Against the prior quarter it is up 151.3%.

Net Income

$9.0M

YoY+244.7%

QoQ+8191.7%

AtriCure, Inc. reported $9.0M in net income in Q2 2026. This represents an increase of 244.7% from the same quarter a year earlier. Against the prior quarter it is up 8191.7%.

EPS (Diluted)

$0.18

YoY+238.5%

AtriCure, Inc. earned $0.18 per diluted share (EPS) in Q2 2026. This represents an increase of 238.5% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

$18.4M

YoY-2.8%

QoQ+334.8%

AtriCure, Inc. generated $18.4M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 2.8% from the same quarter a year earlier. Against the prior quarter it is up 334.8%.

Cash & Debt

$167.8M

YoY+42.4%

QoQ+14.8%

5Y CAGR+19.9%

10Y CAGR+23.8%

AtriCure, Inc. held $167.8M in cash against $61.0M in long-term debt as of Q2 2026.

Shares Outstanding

51M

YoY+2.3%

QoQ+0.4%

5Y CAGR+2.1%

10Y CAGR+4.4%

AtriCure, Inc. had 51M shares outstanding in Q2 2026. This represents an increase of 2.3% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

77.2%

YoY+2.7pp

QoQ-0.2pp

AtriCure, Inc.'s gross margin was 77.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Operating Margin

6.3%

YoY+10.8pp

QoQ+5.9pp

AtriCure, Inc.'s operating margin was 6.3% in Q2 2026, reflecting core business profitability. This is up 10.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.9 percentage points.

Net Margin

5.8%

YoY+10.4pp

QoQ+5.8pp

AtriCure, Inc.'s net profit margin was 5.8% in Q2 2026, showing the share of revenue converted to profit. This is up 10.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.8 percentage points.

Return on Equity

1.7%

YoY+3.1pp

QoQ+1.7pp

AtriCure, Inc.'s ROE was 1.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.

Capital Allocation

R&D Spending

$26.4M

YoY-9.8%

QoQ+8.9%

AtriCure, Inc. invested $26.4M in research and development in Q2 2026. This represents a decrease of 9.8% from the same quarter a year earlier. Against the prior quarter it is up 8.9%.

Capital Expenditures

$3.8M

YoY+41.5%

QoQ-2.2%

5Y CAGR-2.2%

10Y CAGR+9.4%

AtriCure, Inc. invested $3.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 41.5% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.

Share Buybacks

Not reported for Q2 2026.

ATRC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATRC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$569.6M	$534.5M+14.9%	$465.3M+16.5%	$399.2M+20.8%	$330.4M+20.4%	$274.3M+32.8%	$206.5M-10.5%	$230.8M+14.5%	$201.6M+15.4%	$174.7M+12.6%	$155.1M+19.5%	$129.8M+20.8%	$107.5M+31.2%	$81.9M+16.6%	$70.2M+9.1%	$64.4M
Cost of Revenue	$135.0M	$133.7M+13.6%	$117.8M+19.1%	$98.9M+17.1%	$84.4M+23.3%	$68.5M+10353.3%	$655K+3.1%	$635K-19.1%	$785K-12.8%	$900K+44.0%	$625K-98.3%	$36.9M+16.3%	$31.7M+42.0%	$22.3M+10.3%	$20.2M+16.2%	$17.4M
Gross Profit	$434.6M	$400.8M+15.3%	$347.5M+15.7%	$300.4M+22.1%	$245.9M+19.5%	$205.9M+37.9%	$149.3M-12.3%	$170.3M+15.8%	$147.1M+16.6%	$126.2M+13.6%	$111.1M+19.6%	$92.9M+22.6%	$75.8M+27.2%	$59.6M+19.1%	$50.0M+6.4%	$47.0M
R&D Expenses	$98.0M	$99.2M+3.2%	$96.2M+30.1%	$73.9M+28.9%	$57.3M+18.2%	$48.5M+12.6%	$43.1M+4.5%	$41.2M+18.7%	$34.7M+1.7%	$34.1M-4.7%	$35.8M+39.2%	$25.7M+38.4%	$18.6M+38.4%	$13.4M+10.6%	$12.1M+2.4%	$11.9M
SG&A Expenses	$323.7M	$311.0M+6.7%	$291.4M+15.1%	$253.1M+9.5%	$231.3M+13.0%	$204.6M+35.7%	$150.8M-9.8%	$167.1M+29.0%	$129.5M+10.7%	$117.0M+9.9%	$106.4M+13.4%	$93.9M+27.7%	$73.5M+28.9%	$57.0M+26.5%	$45.1M+13.0%	$39.9M
Operating Income	$12.9M	-$9.4M+76.4%	-$40.0M-50.0%	-$26.7M+37.5%	-$42.7M-177.3%	$55.2M+224.8%	-$44.2M-33.5%	-$33.1M-93.4%	-$17.1M+31.4%	-$25.0M+19.8%	-$31.1M-16.5%	-$26.7M-63.3%	-$16.4M-50.2%	-$10.9M-51.3%	-$7.2M-52.1%	-$4.7M
EBITDA	N/A	$12.1M+160.0%	-$20.2M-86.5%	-$10.8M+63.8%	-$29.9M-144.9%	$66.7M+298.2%	-$33.6M-47.8%	-$22.8M-171.8%	-$8.4M+47.2%	-$15.9M+27.4%	-$21.8M-6.8%	-$20.4M-76.4%	-$11.6M-30.6%	-$8.9M-67.4%	-$5.3M-88.6%	-$2.8M
Interest Expense	$5.6M	$5.9M-8.3%	$6.4M-7.5%	$6.9M+38.9%	$5.0M+1.4%	$4.9M+0.7%	$4.9M+18.8%	$4.1M-10.8%	$4.6M+103.5%	$2.3M+25.7%	$1.8M+516.8%	$292K-4.3%	$305K-46.1%	$566K-29.4%	$802K-1.5%	$814K
Income Tax	$1.5M	$1.3M+25.5%	$1.0M+73.3%	$591K+120.5%	$268K+42.6%	$188K+64.9%	$114K-42.7%	$199K-11.9%	$226K+1514.3%	$14K-65.0%	$40K+11.1%	$36K+9.1%	$33K+83.3%	$18K-64.0%	$50K+61.3%	$31K
Net Income	$10.6M	-$11.4M+74.4%	-$44.7M-46.8%	-$30.4M+34.5%	-$46.5M-192.6%	$50.2M+204.2%	-$48.2M-36.8%	-$35.2M-66.5%	-$21.1M+21.4%	-$26.9M+19.3%	-$33.3M-22.5%	-$27.2M-67.9%	-$16.2M-41.4%	-$11.5M-52.1%	-$7.5M-38.1%	-$5.5M
EPS (Basic)	N/A	-$0.24+74.7%	-$0.95-43.9%	-$0.66+35.3%	-$1.02-191.9%	$1.11+197.4%	-$1.14-21.3%	-$0.94	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.21	-$0.24+74.7%	-$0.95-43.9%	-$0.66+35.3%	-$1.02-193.6%	$1.09+195.6%	-$1.14-21.3%	-$0.94	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	48M+1.7%	47M+1.4%	46M+1.2%	46M-0.6%	46M+9.3%	42M+12.1%	38M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$153.6M+12.8%	$141.2M+14.3%	$140.5M+13.1%	$134.3M+15.8%	$136.1M+17.1%	$123.6M+13.6%	$124.3M+16.6%	$115.9M+17.9%
Cost of Revenue	$35.0M+0.9%	$31.9M+3.1%	$35.2M+11.1%	$32.9M+13.1%	$34.7M+17.8%	$31.0M+12.4%	$31.7M+18.4%	$29.1M+19.2%
Gross Profit	$118.6M+16.9%	$109.3M+18.0%	$105.3M+13.7%	$101.3M+16.8%	$101.5M+16.9%	$92.6M+14.0%	$92.6M+16.0%	$86.8M+17.5%
R&D Expenses	$26.4M-9.8%	$24.2M+7.6%	$24.5M-29.9%	$22.9M+9.2%	$29.3M+43.4%	$22.5M+13.5%	$35.0M+68.1%	$21.0M+3.0%
SG&A Expenses	$82.6M+5.3%	$84.5M+11.2%	$78.3M+8.5%	$78.2M+6.8%	$78.4M+6.5%	$76.1M+5.1%	$72.2M+6.6%	$73.2M+18.9%
Operating Income	$9.7M+256.1%	$526K+108.8%	$2.5M+117.2%	$208K+102.8%	-$6.2M+13.6%	-$6.0M+45.5%	-$14.5M-67.5%	-$7.4M+8.5%
EBITDA	$15.2M+2107.0%	$6.1M+1096.9%	$7.9M+183.3%	$5.6M+354.6%	-$759K+68.0%	-$608K+90.2%	-$9.4M-122.8%	-$2.2M+40.5%
Interest Expense	$1.3M-11.5%	$1.3M-5.4%	$1.5M+3.7%	$1.5M-11.9%	$1.5M-7.6%	$1.4M-15.6%	$1.5M-19.3%	$1.7M-5.9%
Income Tax	$471K+80.5%	$286K+19.7%	$604K+127.1%	$181K-43.8%	$261K+3.2%	$239K+30.6%	$266K-28.7%	$322K+585.1%
Net Income	$9.0M+244.7%	$108K+101.6%	$1.8M+111.3%	-$267K+96.6%	-$6.2M+22.7%	-$6.7M+49.2%	-$15.6M-59.0%	-$7.9M+13.3%
EPS (Basic)	$0.18+238.5%	$0.00+100.0%	$0.04+112.1%	-$0.01+94.1%	-$0.13+23.5%	-$0.14+50.0%	-$0.33-57.1%	-$0.17+15.0%
EPS (Diluted)	$0.18+238.5%	$0.00+100.0%	$0.04+112.1%	-$0.01	-$0.13+23.5%	-$0.14+50.0%	-$0.33-57.1%	-$0.17+15.0%
Diluted Shares (Avg)	49M+2.4%	49M+3.5%	N/A	48M	48M+1.7%	47M+1.4%	N/A	47M+1.5%

ATRC Balance Sheet

ATRC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$654.2M+7.4%	$609.3M-0.7%	$613.9M+4.9%	$585.4M-4.9%	$615.3M-13.9%	$714.5M+28.1%	$557.9M+56.4%	$356.8M+33.3%	$267.7M-3.2%	$276.4M+1.2%	$273.1M+72.4%	$158.4M+41.5%	$111.9M+245.2%	$32.4M-4.2%	$33.9M
Current Assets	$322.5M+20.4%	$267.8M+0.6%	$266.2M+23.7%	$215.2M+9.8%	$196.1M-36.1%	$306.7M+114.3%	$143.2M-18.0%	$174.7M+112.3%	$82.3M-4.0%	$85.7M+14.7%	$74.8M-20.1%	$93.5M+78.2%	$52.5M+83.9%	$28.5M-8.5%	$31.2M
Cash & Equivalents	$167.4M+36.4%	$122.7M+45.6%	$84.3M+45.1%	$58.1M+33.1%	$43.7M+4.1%	$41.9M+47.3%	$28.5M-11.6%	$32.2M+47.8%	$21.8M-9.9%	$24.2M+1.9%	$23.8M-16.3%	$28.4M+90.6%	$14.9M+92.1%	$7.8M-20.6%	$9.8M
Short-Term Investments	$0	$0-100.0%	$53.0M-15.9%	$63.0M-16.5%	$75.4M-62.7%	$202.3M+279.4%	$53.3M-42.2%	$92.2M+629.1%	$12.6M-36.2%	$19.8M+83.1%	$10.8M-65.4%	$31.3M+176.2%	$11.3M+166.5%	$4.2M-4.0%	$4.4M
Inventory	$78.5M+4.2%	$75.3M+11.0%	$67.9M+47.8%	$45.9M+17.9%	$39.0M+11.2%	$35.0M+19.1%	$29.4M+30.8%	$22.5M+0.1%	$22.5M+27.1%	$17.7M0.0%	$17.7M+23.9%	$14.3M+39.6%	$10.2M+78.6%	$5.7M-12.9%	$6.6M
Accounts Receivable	$66.7M+10.5%	$60.3M+14.9%	$52.5M+23.0%	$42.7M+29.3%	$33.0M+42.7%	$23.1M-17.5%	$28.0M+11.3%	$25.2M+9.1%	$23.1M+9.4%	$21.1M+8.7%	$19.4M+10.5%	$17.6M+28.6%	$13.7M+37.2%	$9.9M+4.6%	$9.5M
Long-Term Investments	$0	$0	$0-100.0%	$51.5M-50.6%	$104.3M+635.9%	$14.2M+11.9%	$12.7M	$0	$0-100.0%	$3.0M-61.1%	$7.7M-13.4%	$8.9M+12.4%	$7.9M	$0	$0
Goodwill	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M+123.1%	$105.3M0.0%	$105.3M0.0%	$105.3M0.0%	$105.3M+197.5%	$35.4M0.0%	$35.4M	$0	N/A
Total Liabilities	$162.2M+9.4%	$148.4M+0.4%	$147.8M+14.8%	$128.7M-2.2%	$131.6M-56.5%	$302.1M-2.7%	$310.5M+189.2%	$107.4M+0.8%	$106.5M-1.3%	$108.0M+25.0%	$86.4M+234.1%	$25.9M-34.3%	$39.3M+97.4%	$19.9M+9.2%	$18.2M
Current Liabilities	$81.5M+11.0%	$73.4M-1.5%	$74.6M+27.7%	$58.4M+3.4%	$56.4M+14.9%	$49.1M-1.6%	$49.9M+24.1%	$40.2M+26.1%	$31.9M+10.7%	$28.8M-8.7%	$31.6M+23.2%	$25.6M-4.0%	$26.7M+118.9%	$12.2M+12.9%	$10.8M
Non-Current Liabilities	$80.7M+7.7%	$74.9M+2.4%	$73.2M+4.1%	$70.3M-6.4%	$75.1M-70.3%	$253.0M-2.9%	$260.6M+288.0%	$67.2M-10.0%	$74.6M-5.7%	$79.2M+44.4%	$54.8M+24482.5%	$223K-98.2%	$12.6M+63.5%	$7.7M+3.9%	$7.4M
Long-Term Debt	$61.9M0.0%	$61.9M+2.1%	$60.6M+6.6%	$56.8M-4.9%	$59.7M+11.8%	$53.4M-10.4%	$59.6M+67.6%	$35.6M+47.6%	$24.1M+0.9%	$23.9M	N/A	$74K-98.3%	$4.4M-31.1%	$6.4M+30.1%	$4.9M
Total Equity	$491.9M+6.7%	$461.0M-1.1%	$466.2M+2.1%	$456.8M-5.6%	$483.8M+17.3%	$412.4M+66.7%	$247.3M-0.8%	$249.4M+54.7%	$161.2M-4.3%	$168.4M-9.8%	$186.7M+40.9%	$132.5M+82.5%	$72.6M+480.8%	$12.5M-19.9%	$15.6M
Retained Earnings	-$413.2M-2.8%	-$401.8M-12.5%	-$357.1M-9.3%	-$326.6M-16.6%	-$280.2M+15.2%	-$330.4M-17.1%	-$282.2M-14.2%	-$247.0M-9.4%	-$225.9M-13.5%	-$199.0M-20.1%	-$165.6M-19.7%	-$138.4M-13.3%	-$122.2M-10.3%	-$110.8M-7.3%	-$103.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$676.6M+11.1%	$644.0M+8.8%	$654.2M+7.4%	$635.4M+3.3%	$608.8M+1.9%	$591.6M0.0%	$609.3M-0.7%	$615.1M+2.5%
Current Assets	$345.5M+27.4%	$313.7M+24.7%	$322.5M+20.4%	$301.1M+11.8%	$271.3M+7.3%	$251.5M+2.6%	$267.8M+0.6%	$269.3M+6.6%
Cash & Equivalents	$167.8M+42.4%	$146.2M+46.3%	$167.4M+36.4%	$147.9M+13.4%	$117.8M+11.1%	$99.9M+53.7%	$122.7M+45.6%	$130.3M+61.7%
Short-Term Investments	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%
Inventory	$83.9M+9.9%	$81.1M+8.3%	$78.5M+4.2%	$79.0M+3.1%	$76.3M+3.7%	$74.9M+4.1%	$75.3M+11.0%	$76.5M+23.7%
Accounts Receivable	$80.0M+21.2%	$71.3M+12.6%	$66.7M+10.5%	$63.0M+14.7%	$66.0M+18.8%	$63.3M+14.5%	$60.3M+14.9%	$54.9M+6.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%	$234.8M0.0%
Total Liabilities	$160.2M+11.0%	$152.3M+11.2%	$162.2M+9.4%	$158.9M+5.9%	$144.4M+6.8%	$137.0M+1.3%	$148.4M+0.4%	$150.0M+9.2%
Current Liabilities	$81.9M+19.0%	$73.2M+19.6%	$81.5M+11.0%	$77.8M+4.6%	$68.8M+12.4%	$61.2M-0.1%	$73.4M-1.5%	$74.4M-9.8%
Non-Current Liabilities	$78.3M+3.7%	$79.1M+4.4%	$80.7M+7.7%	$81.1M+7.2%	$75.5M+2.1%	$75.8M+2.3%	$74.9M+2.4%	$75.6M+37.7%
Long-Term Debt	$61.0M-1.4%	$61.0M-1.4%	$61.9M0.0%	$61.9M0.0%	$61.9M0.0%	$61.9M0.0%	$61.9M+2.1%	$61.9M+46.8%
Total Equity	$516.4M+11.2%	$491.7M+8.2%	$491.9M+6.7%	$476.5M+2.5%	$464.5M+0.5%	$454.6M-0.4%	$461.0M-1.1%	$465.0M+0.5%
Retained Earnings	-$404.1M+2.5%	-$413.1M-1.1%	-$413.2M-2.8%	-$415.0M-7.5%	-$414.7M-9.6%	-$408.5M-10.3%	-$401.8M-12.5%	-$386.2M-11.2%

ATRC Cash Flow Statement

ATRC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$64.9M	$57.3M+369.8%	$12.2M+172.2%	$4.5M+120.3%	-$22.1M-60.7%	-$13.8M+30.6%	-$19.9M-25.7%	-$15.8M-279.1%	-$4.2M+53.4%	-$8.9M+40.8%	-$15.1M-92.8%	-$7.8M+63.7%	-$21.6M-313.6%	-$5.2M-169.7%	-$1.9M+2.5%	-$2.0M
Depreciation & Amortization	N/A	$21.6M+9.1%	$19.8M+24.9%	$15.8M+24.4%	$12.7M+11.0%	$11.5M+8.1%	$10.6M+2.3%	$10.4M+18.4%	$8.8M-4.1%	$9.1M-1.8%	$9.3M+48.1%	$6.3M+31.5%	$4.8M+136.3%	$2.0M+6.4%	$1.9M-1.2%	$1.9M
Stock-Based Compensation	N/A	$44.7M+10.6%	$40.4M+13.1%	$35.7M+24.2%	$28.8M+2.5%	$28.1M+24.0%	$22.6M+25.9%	$18.0M+9.0%	$16.5M+12.9%	$14.6M+24.9%	$11.7M+30.0%	$9.0M+18.8%	$7.6M+145.8%	$3.1M-11.2%	$3.5M+18.0%	$2.9M
Capital Expenditures	$11.8M	$9.1M-21.0%	$11.5M-4.5%	$12.0M-28.9%	$16.9M+73.1%	$9.8M+85.5%	$5.3M-56.8%	$12.2M+96.1%	$6.2M-2.7%	$6.4M-17.0%	$7.7M-42.8%	$13.4M+144.1%	$5.5M+92.3%	$2.9M-4.1%	$3.0M+96.1%	$1.5M
Free Cash Flow	$53.1M	$48.3M+6381.1%	$745K+109.9%	-$7.5M+80.7%	-$39.0M-65.8%	-$23.5M+6.3%	-$25.1M+10.2%	-$28.0M-169.6%	-$10.4M+32.3%	-$15.3M+32.8%	-$22.8M-7.2%	-$21.3M+21.5%	-$27.1M-235.2%	-$8.1M-64.3%	-$4.9M-40.3%	-$3.5M
Investing Cash Flow	-$12.8M	-$14.6M-148.1%	$30.2M+38.6%	$21.8M-50.4%	$44.0M+87.2%	$23.5M+115.0%	-$156.2M-7175.2%	-$2.1M+97.5%	-$85.4M-2370.8%	$3.8M+131.1%	-$12.1M-15.0%	-$10.5M	N/A	-$14.2M-405.9%	-$2.8M-202.7%	$2.7M
Financing Cash Flow	-$1.9M	$1.2M+132.6%	-$3.6M-11159.4%	-$32K+99.5%	-$7.1M+7.6%	-$7.6M-104.0%	$189.4M+1217.7%	$14.4M-85.7%	$100.2M+3529.6%	$2.8M-90.0%	$27.7M+98.4%	$14.0M	N/A	$26.8M+907.8%	$2.7M-45.1%	$4.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$22.2M+2.7%	-$4.0M+63.8%	$20.0M+243.2%	$26.7M+33.6%	$21.6M+192.9%	-$11.0M+47.5%	$5.8M+44.8%	$20.0M+1214.3%
Depreciation & Amortization	$5.6M+2.5%	$5.5M+3.5%	$5.4M+5.5%	$5.4M+4.6%	$5.4M+13.3%	$5.3M+13.6%	$5.1M+14.7%	$5.2M+18.9%
Stock-Based Compensation	$12.3M+8.3%	$11.3M+17.1%	N/A	$12.4M+19.9%	$11.4M+9.4%	$9.6M+3.9%	N/A	$10.4M+19.7%
Capital Expenditures	$3.8M+41.5%	$3.9M+76.6%	$1.6M-40.5%	$2.6M-27.8%	$2.7M+11.7%	$2.2M-21.4%	$2.7M-3.3%	$3.6M-0.6%
Free Cash Flow	$18.4M-2.8%	-$7.8M+40.6%	$18.4M+486.2%	$24.1M+47.1%	$19.0M+279.4%	-$13.2M+44.5%	$3.1M+152.7%	$16.4M+877.8%
Investing Cash Flow	-$3.8M+50.8%	-$3.9M-129.1%	-$2.6M+82.3%	-$2.6M-159.3%	-$7.7M-124.8%	-$1.7M-117.4%	-$14.7M-427.4%	$4.4M-63.0%
Financing Cash Flow	$3.3M-4.6%	-$13.3M-28.4%	$2.1M+20.7%	$6.0M+1897.0%	$3.4M+19.8%	-$10.3M-31.3%	$1.7M-26.3%	-$333K-352.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATRC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATRC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	75.0%+0.3pp	74.7%-0.5pp	75.2%+0.8pp	74.4%-0.6pp	75.0%+2.7pp	72.3%-1.5pp	73.8%+0.8pp	73.0%+0.8pp	72.2%+0.6pp	71.6%+0.1pp	71.6%+1.1pp	70.5%-2.2pp	72.7%+1.5pp	71.2%-1.8pp	73.0%
Operating Margin	-1.8%+6.8pp	-8.6%-1.9pp	-6.7%+6.2pp	-12.9%-33.0pp	20.1%+41.5pp	-21.4%-7.1pp	-14.3%-5.9pp	-8.5%+5.8pp	-14.3%+5.8pp	-20.1%+0.5pp	-20.6%-5.4pp	-15.2%-1.9pp	-13.3%-3.1pp	-10.3%-2.9pp	-7.3%
Net Margin	-2.1%+7.5pp	-9.6%-2.0pp	-7.6%+6.4pp	-14.1%-32.4pp	18.3%+41.6pp	-23.3%-8.1pp	-15.3%-4.8pp	-10.5%+4.9pp	-15.4%+6.1pp	-21.5%-0.5pp	-21.0%-5.9pp	-15.1%-1.1pp	-14.0%-3.3pp	-10.7%-2.3pp	-8.5%
Return on Equity	-2.3%+7.4pp	-9.7%-3.2pp	-6.5%+3.6pp	-10.2%-20.6pp	10.4%+22.1pp	-11.7%+2.6pp	-14.2%-5.8pp	-8.5%+8.2pp	-16.7%+3.1pp	-19.8%-5.2pp	-14.6%-2.4pp	-12.2%+3.6pp	-15.8%+44.5pp	-60.3%-25.3pp	-34.9%
Return on Assets	-1.8%+5.6pp	-7.3%-2.4pp	-5.0%+3.0pp	-7.9%-16.1pp	8.2%+14.9pp	-6.7%-0.4pp	-6.3%-0.4pp	-5.9%+4.1pp	-10.1%+2.0pp	-12.1%-2.1pp	-10.0%+0.3pp	-10.2%0.0pp	-10.2%+13.0pp	-23.2%-7.1pp	-16.1%
Current Ratio	3.96+0.3x	3.65+0.1x	3.57-0.1x	3.69+0.2x	3.47-2.8x	6.24+3.4x	2.87-1.5x	4.34+1.8x	2.58-0.4x	2.97+0.6x	2.37-1.3x	3.65+1.7x	1.96-0.4x	2.34-0.5x	2.89
Debt-to-Equity	0.130.0x	0.130.0x	0.130.0x	0.120.0x	0.120.0x	0.13-0.1x	0.24+0.1x	0.140.0x	0.150.0x	0.14-0.3x	0.46+0.5x	0.00-0.1x	0.06-0.5x	0.51+0.2x	0.32
Asset Turnover	0.82+0.1x	0.76+0.1x	0.65+0.1x	0.56+0.1x	0.45+0.2x	0.29-0.1x	0.41-0.2x	0.57-0.1x	0.65+0.1x	0.56+0.1x	0.48-0.2x	0.68-0.1x	0.73-1.4x	2.17+0.3x	1.90
FCF Margin	9.0%+8.9pp	0.2%+2.0pp	-1.9%+9.9pp	-11.8%-3.2pp	-8.6%+3.6pp	-12.2%0.0pp	-12.1%-7.0pp	-5.1%+3.6pp	-8.8%+5.9pp	-14.7%+1.7pp	-16.4%+8.8pp	-25.2%-15.4pp	-9.9%-2.9pp	-7.0%-1.6pp	-5.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	77.2%+2.7pp	77.4%+2.5pp	75.0%+0.4pp	75.5%+0.6pp	74.5%-0.2pp	74.9%+0.3pp	74.5%-0.4pp	74.9%-0.3pp
Operating Margin	6.3%+10.8pp	0.4%+5.2pp	1.8%+13.5pp	0.1%+6.5pp	-4.5%+1.6pp	-4.8%+5.2pp	-11.7%-3.6pp	-6.4%+1.8pp
Net Margin	5.8%+10.4pp	0.1%+5.5pp	1.3%+13.8pp	-0.2%+6.6pp	-4.5%+2.3pp	-5.5%+6.7pp	-12.5%-3.3pp	-6.8%+2.4pp
Return on Equity	1.7%+3.1pp	0.0%+1.5pp	0.4%+3.7pp	-0.1%+1.6pp	-1.3%+0.4pp	-1.5%+1.4pp	-3.4%-1.3pp	-1.7%+0.3pp
Return on Assets	1.3%+2.3pp	0.0%+1.2pp	0.3%+2.8pp	0.0%+1.2pp	-1.0%+0.3pp	-1.1%+1.1pp	-2.5%-1.0pp	-1.3%+0.2pp
Current Ratio	4.22+0.3x	4.29+0.2x	3.96+0.3x	3.87+0.3x	3.94-0.2x	4.11+0.1x	3.65+0.1x	3.62+0.6x
Debt-to-Equity	0.120.0x	0.120.0x	0.130.0x	0.130.0x	0.130.0x	0.140.0x	0.130.0x	0.130.0x
Asset Turnover	0.230.0x	0.220.0x	0.210.0x	0.210.0x	0.220.0x	0.210.0x	0.200.0x	0.190.0x
FCF Margin	12.0%-1.9pp	-5.6%+5.1pp	13.1%+10.6pp	18.0%+3.8pp	13.9%+9.6pp	-10.7%+11.2pp	2.5%+1.4pp	14.1%+16.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AtriCure, Inc. ATRC	FY2025	$534.5M	-$11.4M	-2.1%	$2.9B	57/100
Anbio Biotechnology NNNN	FY2025	$8.6M	$6.4M	74.1%	$187.0M	71/100
Staar Surgical Co STAA	FY2025	$239.4M	-$80.4M	-33.6%	$1.1B	33/100
Azenta, Inc. AZTA	FY2025	$593.8M	-$55.8M	-9.4%	$1.7B	49/100
BioLife Solutions Inc. BLFS	FY2025	$96.2M	-$4.6M	-4.8%	$1.9B	69/100
Kestra Medical Technologies, Ltd. KMTS	FY2026	$95.1M	-$131.6M	N/A	$1.6B	50/100

Where AtriCure, Inc. Ranks

Frequently Asked Questions

What is AtriCure, Inc.'s annual revenue?

AtriCure, Inc. (ATRC) reported $534.5M in total revenue for fiscal year 2025. This represents a 14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AtriCure, Inc.'s revenue growing?

AtriCure, Inc. (ATRC) revenue grew by 14.9% year-over-year, from $465.3M to $534.5M in fiscal year 2025.

Is AtriCure, Inc. profitable?

No, AtriCure, Inc. (ATRC) reported a net income of -$11.4M in fiscal year 2025, with a net profit margin of -2.1%.

What is AtriCure, Inc.'s EBITDA?

AtriCure, Inc. (ATRC) had EBITDA of $12.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does AtriCure, Inc. have?

As of fiscal year 2025, AtriCure, Inc. (ATRC) had $167.4M in cash and equivalents against $61.9M in long-term debt.

What is AtriCure, Inc.'s gross margin?

AtriCure, Inc. (ATRC) had a gross margin of 75.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is AtriCure, Inc.'s operating margin?

AtriCure, Inc. (ATRC) had an operating margin of -1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is AtriCure, Inc.'s net profit margin?

AtriCure, Inc. (ATRC) had a net profit margin of -2.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is AtriCure, Inc.'s return on equity (ROE)?

AtriCure, Inc. (ATRC) has a return on equity of -2.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is AtriCure, Inc.'s free cash flow?

AtriCure, Inc. (ATRC) generated $48.3M in free cash flow during fiscal year 2025. This represents a 6381.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AtriCure, Inc.'s operating cash flow?

AtriCure, Inc. (ATRC) generated $57.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are AtriCure, Inc.'s total assets?

AtriCure, Inc. (ATRC) had $654.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are AtriCure, Inc.'s capital expenditures?

AtriCure, Inc. (ATRC) invested $9.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does AtriCure, Inc. spend on research and development?

AtriCure, Inc. (ATRC) invested $99.2M in research and development during fiscal year 2025.

How many shares does AtriCure, Inc. have outstanding?

AtriCure, Inc. (ATRC) had 50M shares outstanding as of fiscal year 2025.

What is AtriCure, Inc.'s current ratio?

AtriCure, Inc. (ATRC) had a current ratio of 3.96 as of fiscal year 2025, which is generally considered healthy.

What is AtriCure, Inc.'s debt-to-equity ratio?

AtriCure, Inc. (ATRC) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AtriCure, Inc.'s return on assets (ROA)?

AtriCure, Inc. (ATRC) had a return on assets of -1.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is AtriCure, Inc.'s P/E ratio?

AtriCure, Inc. (ATRC) trades at 274x earnings, its market capitalization divided by net income of $10.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.9B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AtriCure, Inc.'s price-to-sales ratio?

AtriCure, Inc. (ATRC) trades at 5.1x sales, its market capitalization divided by revenue of $569.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.9B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AtriCure, Inc.'s Altman Z-Score?

AtriCure, Inc. (ATRC) has an Altman Z-Score of 11.03, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is AtriCure, Inc.'s Piotroski F-Score?

AtriCure, Inc. (ATRC) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AtriCure, Inc.'s earnings high quality?

AtriCure, Inc. (ATRC) reported a net loss of $11.4M while generating $57.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can AtriCure, Inc. cover its interest payments?

AtriCure, Inc. (ATRC) reported an operating loss of $9.4M against $5.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is AtriCure, Inc.?

AtriCure, Inc. (ATRC) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.